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Abstract 
Isoniazid induced sideroblastic anemia is a
rare  event.  We  report  case  of  a  45  year  old
Caucasian women with development of severe
anaemia  4  month  after  introduction  of
Isoniazid  as  part  of  Tuberculosis  treatment.
While haemoglobin fell to 47 g/L and erythro-
cyte count to 1.5 G/L, reticulocytes were very
low (reticulocyte production index of 0.48), but
bone marrow aspirate showed an accelerated
erythropoiesis with ringsideroblasts. Anaemia
rapidly  resolved  after  cessation  of  Isoniazid.
We postulate an Isoniazid induced inhibition
of the δ-Amino-levulinat-synthase resulting in
marked depletion of heam synthesis. 
Case Report
A 45-year old Caucasian women was diag-
nosed  with  tuberculous  spondylitis  and
paraspinal  abscess.  M.tuberculosis  could  be
isolated from intraoperativ biopsy; resistance
testing revealed a completely sensitive strain.
On  July  2,  treatment  was  started  with
rifampicin (RIF) 600 mg/day, Isoniazid (INH)
300 mg/day, Pyrazinamid (PZA) 1500 mg/day
and  Ethambutol  (ETB)  1200  mg/day.  After
results of the resistance test where available,
Ethambutol was stopped. Liver enzymes where
elevated at one occasion but fell into normal
range spontaneously. After two month of com-
bination  therapy  RIF/INH/PZA,  PZA  was
stopped according to international guidelines.
Four  month  after  begin  of  treatment,  liver
enzymes rose again, and INH was replaced by
moxifloxacin.  Liver  enzymes  fell  to  normal
level, but the disturbed liver enzymes where
later interpreted as alcohol induced. December
12, progression of the paraspinal abscess was
diagnosed, and the treatment was stopped for
allowing new biopsies. On January 5, 2010, the
patient  was  re-operated  but  mycobacteria
couldn’t  be  cultured  in  this  second  biopsy.
Antimycobacterial  treatment  was  reinstalled
January  7.  Because  of  possible  non-compli-
ance, we started again with a four drug combi-
nation  for  one  month,  followed  by
INH/RIF/PZA. The patient then did not come to
the  visits  until  April  12.    At  that  time  the
patient  complaint  about  shortness  of  breath
NYHA 2. Haemoglobin level had fallen to 47
gram/L with a mean cell volume of 96 fl and a
mean cell haemoglobin concentration of 334
g/L. PZA was stopped, but the other treatment
was not changed. Two packs of red blood cells
where transfused the day after. One week later,
haemoglobin level had risen only to 51 gram/L.
Bone marrow aspiration and biopsy was per-
formed  on  April  20  (under  Isoniazid-treat-
ment).  Isoniazid  was  substituted  by  moxi-
floxacin,  rifampicin  was  not  changed.  Again
two  packs  of  red  cell  where  transfused.
Haemoglobin level rose to 89 gram/L, and retic-
ulocyte production index rose from 0.48 to 2.9
one week after cessation of Isoniazid. No fur-
ther transfusions where needed, and one week
later,  haemoglobin  level  was  at  100  gram/L
(Figure 1). Folic acid, Cobalamine and Ferritin
values where in normal range, Parvovirus B19
PCR was negative. Bone marrow was not typi-
cal for PRCA, as it showed an enhanced, dys-
plastic  erythropoiesis  with  30%  ringsiderob-
lasts (Figures 2 and 3). No rearrangement of
the MLL gene could be observed by fluorescent
in situ hybridisation (FISH). Erythrocyte count
in peripheral blood was 1.5 G/L. Erythropoietin
level was high, 1171 IU/L (normal range 12-23)
and erythropoietin antibodies negative. Under
treatment  with  rifampicin/moxifloxacin,
haemoglobin  levels  returned  to  normal  level
and remained stable. 
Discussion
Two major forms of anemia are decribed as
side effect of treatment with Isoniazid. Pure
red cell aplasia (PRCA), a  syndrome character-
ized  by  severe  normochromic  normocytic
anaemia, reticulocytopenia, and isolated ery-
throblastopenia  in  the  bone  marrow1 and
sideroblastic  anemia  (SA),  characterized  by
deficient haem synthesis and an increase of
ringsideroblasts in bone marrow. Both are rare
conditions. As the bone marrow did show an
increased  erythropoiesis  with  ringsiderob-
lasts, we postulate a sideroblastic anemia. This
disorder is generally divided in diseases of the
haem synthesis pathway or of other mitochon-
drial pathways.2 Drug induced SA is due to a
disorder in haem synthesis.2 Of tuberculostat-
ic drugs, Isoniazid, Rifampin and Pyrazinamid
are described as cause of SA.3-5 It is not clear if
rifampin really induces SA alone. The reports
show an SA in combination with Isoniazid, and
Rifampin is frequently prescribed in prosthetic
joint  infections  without  supplementation  of
pyridoxine. If there would be a risk of develop-
ment of SA by Rifampin alone, it should be
seen more often in these situations. The fre-
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Figure 1. Blood values and treatment duration.
RIF, rifampin; INH, isoniazid; PZA, pyrazi-
namide;  ETB,  ethambutol;  MOF,  moxi-
floxacin; RPI, reticulocyte production index.
Figure 2. Hypercellular bone marrow aspi-
rate with dysplastic erythropoiesis.
Figure 3. Ringsideroblasts.[page 4] [Hematology Reports 2011; 3:e2]
quency of Isoniazid induced SA is not clear,
and only 8 cases are described in literature,3,5-10
probably  due  to  the  generally  prescribed  co-
medication with pyridoxine. Some additional
cases described as pyridoxine responsive ane-
mia due to tuberculosis treatment may in fact
also  have  been  SA.11-13 The  mechanism  of
Isoniazid induced SA is an inhibition of the δ-
aminolevulinate  synthase-214 resulting  in  a
depletion of haem synthesis.15 Pyridoxine acts
as a co-factor in synthesis of δ-aminolevuli-
nate,  and  is  inhibited  by  Isoniazid2
Substitution  of  pyridoxine  is  recommended
during  treatment  with  Isoniazid,  and  the
patient  was  also  treated  according  to  these
guidelines.16 While  pyridoxine  unresponsive-
ness has been described in hereditary SA, the
situation in Isoniazid induced SA is not clear.
In  most  cases,3,5,7,9 no  pyridoxine  was  given
during treatment with Isoniazid, and both sup-
plementation and withdrawal of Isoniazid was
performed  after  diagnosis  of  SA.  We  rather
postulate a malcompliance in pyridoxine sup-
plementation  than  a  non  responsiveness  in
our patient. Haden et al could demonstrate a
steep rise in haemoglobin level with pyridox-
ine supplementation while the complete tuber-
culous treatment including Isoniazid was not
changed.9 Although Isoniazid induced SA is a
rare condition with known pathogenesis, clini-
cians  should  be  aware  of  the  potential  side
effect of the old drug regularly used for treat-
ment of active and latent tuberculosis. 
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